Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 4/2013

01-08-2013

Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study

Authors: Giuseppe Derosa, Elena Fogari, Angela D’Angelo, Lucio Bianchi, Aldo Bonaventura, Davide Romano, Pamela Maffioli

Published in: Inflammation | Issue 4/2013

Login to get access

Abstract

We evaluated the levels of some inflammatory adipocytokines in 363 obese and 365 non-obese subjects. We measured: body mass index (BMI), waist circumference (WC), fasting plasma glucose, fasting plasma insulin (FPI), homeostasis model assessment (HOMA) index, blood pressure, lipid profile, retinol binding protein-4 (RBP-4), vaspin, omentin-1, leptin, interleukin-6 (IL-6), visfatin, resistin, adiponectin (ADN), adipsin, tumor necrosis factor-α (TNF-α), and high sensitivity C-reactive protein (Hs-CRP). We observed higher BMI, WC, FPI, HOMA index, TC, LDL-C, RBP-4, leptin, IL-6, adipsin, Hs-CRP, vaspin, resistin and TNF-α levels, and lower visfatin, and ADN levels in obese compared to non-obese subjects. Higher WC correlated with lower ADN and visfatin levels, and higher vaspin levels. Higher HOMA index correlated with higher resistin, adipsin, RBP-4, and leptin concentrations, while higher leptin levels correlated with higher TNF-α, Hs-CRP, and IL-6 concentration, and lower ADN values. We confirmed obese subjects’ predisposition to develop dysmetabolic disease and hormonal dysfunctions.
Literature
1.
Van Gaal, L.F., I.L. Mertens, and C.E. De Block. 2006. Mechanisms linking obesity with cardiovascular disease. Nature 444: 875–880.PubMedCrossRef
2.
Stevens, J., J. Cai, E.R. Pamuk, D.F. Williamson, M.J. Thun, and J.L. Wood. 1998. The effect of age on the association between body-mass index and mortality. The New England Journal of Medicine 338(1): 1–7.PubMedCrossRef
3.
Laimer, M., S. Kaser, M. Kranebitter, A. Sandhofer, G. Mühlmann, H. Schwelberger, H. Weiss, J.R. Patsch, and C.F. Ebenbichler. 2005. Effect of pronounced weight loss on the nontraditional cardiovascular risk marker matrix metalloproteinase-9 in middle-aged morbidly obese women. International Journal of Obesity 29(5): 498–501.PubMed
4.
Ahima, R.S. 2000. Leptin and the neuroendocrinology of fasting. Frontiers of Hormone Research 26: 42–56.PubMedCrossRef
5.
Flier, J.S. 2004. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116(2): 337–350.PubMedCrossRef
6.
Hausman, G.J., and R.L. Richardson. 2004. Adipose tissue angiogenesis. Journal of Animal Science 82(3): 925–934.PubMed
7.
Rupnick, M.A., D. Panigrahy, C.Y. Zhang, S.M. Dallabrida, B.B. Lowell, R. Langer, and M.J. Folkman. 2002. Adipose tissue mass can be regulated through the vasculature. Proceedings of the National Academy of Sciences of the United States of America 99(16): 10730–10735.PubMedCrossRef
8.
Trayhurn, P., and I.S. Wood. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. British Journal of Nutrition 92(3): 347–355.PubMedCrossRef
9.
Weisberg, S.P., D. McCann, M. Desai, M. Rosenbaum, R.L. Leibel, and A.W. Ferrante Jr. 2003. Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 112(12): 1796–1808.PubMed
10.
Derosa, G., I. Ferrari, A. D'Angelo, C. Tinelli, S.A. Salvadeo, L. Ciccarelli, M.N. Piccinni, A. Gravina, F. Ramondetti, P. Maffioli, and A.F. Cicero. 2008. Matrix metalloproteinase-2 and -9 levels in obese patients. Endothelium 15(4): 219–224.PubMedCrossRef
11.
Sluijter, J.P., D.P. de Kleijn, and G. Pasterkamp. 2006. Vascular remodeling and protease inhibition—bench to bedside. Cardiovascular Research 69(3): 595–603.PubMedCrossRef
12.
World Health Organization. 1997. Obesity: preventing and managing the global epidemic. Report of WHO Consultation on Obesity. Geneva: WHO.
13.
American Diabetes Association. 2001. Screening for diabetes (Position Statement). Diabetes Care 24: S21–S24.
14.
European Diabetes Policy Group 1999. 1999. A desktop guide to type 2 diabetes mellitus. Diabetic Medicine 16(9): 716–730.CrossRef
15.
Heding, L.G. 1972. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8(4): 260–266.PubMedCrossRef
16.
Matthews, D.R., J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher, and R.C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.PubMedCrossRef
17.
Wallace, T.M., J.C. Levy, and D.R. Matthews. 2004. Use and abuse of HOMA modeling. Diabetes Care 27: 1487–1495.PubMedCrossRef
18.
Klose, S., and K. Borner. 1978. Enzymatische Bestimmung des Gesamtcholesterins mit dem [Enzymatic dosage of total cholesterolemia by Greiner Selective Analyzer (GSA II)]. Journal of Clinical Chemistry and Clinical Biochemistry 15: 121–130.
19.
Wahlefeld, A.W. 1974. Triglycerides determination after enzymatic hydrolysis. In Methods of enzymatic analysis, 2 English edth ed, ed. H.U. Bergmeyer, 18–31. New York: Academic Press.
20.
Havel, R.J., H.A. Eder, and J.H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation 34: 1345–1353.PubMedCrossRef
21.
Friedewald, W.T., R.I. Levy, and D.S. Fredrickson. 1972. Estimation of the concentration of low density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18: 499–502.PubMed
22.
Takebayashi, K., M. Suetsugu, S. Wakabayashi, Y. Aso, and T. Inumai. 2007. Retinol binding protein-4 and clinical features of type 2 diabetes patients. Journal of Clinical Endocrinology and Metabolism 92: 2712–2719.PubMedCrossRef
23.
Hida, K., J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences 102: 10610–10615.CrossRef
24.
De Souza Batista, C.M., R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, J. Pray, K. Ndubuizu, S. Patil, A. Schwartz, M. Kligman, S.K. Fried, D.W. Gong, A.R. Shuldiner, T.I. Pollin, and J.C. McLenithan. 2007. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56(6): 1655–1661.PubMedCrossRef
25.
26.
Korner, A., A. Garten, M. Bluher, R. Tauscher, J. Kratzsch, and W. Kiess. 2007. Molecular characteristics of serum visfatin and differential detection by immunoassays. Journal of Clinical Endocrinology and Metabolism 92: 4783–4791.PubMedCrossRef
27.
Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Medicine 7: 941–946.PubMedCrossRef
28.
Yannakoulia, M., N. Yiannakouris, S. Bluher, A.L. Matalas, D. Klimis-Zacas, and C.S. Mantzoros. 2003. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. Journal of Clinical Endocrinology and Metabolism 88: 1730–1736.PubMedCrossRef
29.
Misra, A., and A. Garg. 1996. Leptin: its receptor and obesity. Journal of Investigative Medicine 44: 540–548.PubMed
30.
Cook, K.S., D.L. Groves, H.Y. Min, and B.M. Spiegelman. 1985. Proceedings of the National Academy of Sciences of the United States of America 82: 6480–6484.PubMedCrossRef
31.
Zhang, M., and K. Tracey. 1988. The cytokine handbook, 3rd ed. San Diego: Academic Press.
32.
Rifai, N., R.P. Tracy, and P.M. Ridker. 1999. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clinical Chemistry 45(12): 2136–2141.PubMed
33.
Gu, P., and A. Xu. 2013. Interplay between adipose tissue and blood vessels in obesity and vascular dysfunction. Reviews in Endocrine & Metabolic Disorders. doi:10.​1007/​s11154-012-9230-8.
34.
Yang, Q., T.E. Graham, N. Mody, F. Preitner, O.D. Peroni, J.M. Zabolotny, K. Kotani, L. Quadro, and B.B. Kahn. 2005. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 436(7049): 356–362.PubMedCrossRef
35.
Hida, K., J. Wada, J. Eguchi, H. Zhang, M. Baba, A. Seida, I. Hashimoto, T. Okada, A. Yasuhara, A. Nakatsuka, K. Shikata, S. Hourai, J. Futami, E. Watanabe, Y. Matsuki, R. Hiramatsu, S. Akagi, H. Makino, and Y.S. Kanwar. 2005. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proceedings of the National Academy of Sciences of the United States of America 102(30): 10610–10615.PubMedCrossRef
36.
Youn, B.S., N. Klöting, J. Kratzsch, N. Lee, J.W. Park, E.S. Song, K. Ruschke, A. Oberbach, M. Fasshauer, M. Stumvoll, and M. Blüher. 2008. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57(2): 372–377.PubMedCrossRef
37.
El-Mesallamy, H.O., D.H. Kassem, E. El-Demerdash, and A.I. Amin. 2011. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60(1): 63–70.PubMedCrossRef
38.
Yang, R.Z., M.J. Lee, H. Hu, J. Pray, H.B. Wu, B.C. Hansen, A.R. Shuldiner, S.K. Fried, J.C. McLenithan, and D.W. Gong. 2006. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of Physiology, Endocrinology and Metabolism 290(6): E1253–E1261.CrossRef
39.
Schäffler, A., M. Neumeier, H. Herfarth, A. Fürst, J. Schölmerich, and C. Büchler. 2005. Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue. Biochimica et Biophysica Acta 1732(1–3): 96–102.PubMedCrossRef
40.
Kralisch, S., J. Klein, M. Bluher, R. Paschke, M. Stumvoll, and M. Fasshauer. 2005. Therapeutic perspectives of adipocytokines. Expert Opinion on Pharmacotherapy 6: 863–872.PubMedCrossRef
41.
Fukuhara, A., M. Matsuda, M. Nishizawa, K. Segawa, M. Tanaka, K. Kishimoto, Y. Matsuki, M. Murakami, T. Ichisaka, H. Murakami, E. Watanabe, T. Takagi, M. Akiyoshi, T. Ohtsubo, S. Kihara, S. Yamashita, M. Makishima, T. Funahashi, S. Yamanaka, R. Hiramatsu, Y. Matsuzawa, and I. Shimomura. 2005. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708): 426–430.PubMedCrossRef
42.
43.
Li, R.Z., X.Y. Ma, X.F. Hu, S.X. Kang, S.K. Chen, K. Cianflone, and H.L. Lu. 2012. Elevated visfatin levels in obese children are related to proinflammatory factors. Journal of Pediatric Endocrinology & Metabolism 14: 1–8.CrossRef
44.
Olszanecka-Glinianowicz, M., P. Kocełak, M. Nylec, J. Chudek, and B. Zahorska-Markiewicz. 2012. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Archives of Medical Science 8(2): 214–218.PubMedCrossRef
45.
Azuma, K., S. Oguchi, Y. Matsubara, T. Mamizuka, M. Murata, H. Kikuchi, K. Watanabe, F. Katsukawa, H. Yamazaki, A. Shimada, and T. Saruta. 2004. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Hormone and Metabolic Research 36(8): 564–570.PubMedCrossRef
46.
Bouchard, L., S.J. Weisnagel, J.C. Engert, T.J. Hudson, C. Bouchard, M.C. Vohl, and L. Pérusse. 2004. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Québec Family Study. Journal of Endocrinological Investigation 27(11): 1003–1009.PubMed
47.
McTernan, P.G., F.M. Fisher, G. Valsamakis, R. Chetty, A. Harte, C.L. McTernan, P.M. Clark, S.A. Smith, A.H. Barnett, and S. Kumar. 2003. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. Journal of Clinical Endocrinology and Metabolism 88(12): 6098–6106.PubMedCrossRef
48.
Ohmori, R., Y. Momiyama, R. Kato, H. Taniguchi, M. Ogura, M. Ayaori, H. Nakamura, and F. Ohsuzu. 2005. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. Journal of the American College of Cardiology 46(2): 379–380.PubMedCrossRef
49.
Jackson, M.B., and R.S. Ahima. 2006. Neuroendocrine and metabolic effects of adipocyte-derived hormones. Clinical Science 110: 143–152.PubMedCrossRef
50.
Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends in Endocrinology and Metabolism 13: 84–89.PubMedCrossRef
51.
Bouskila, M., U.B. Pajvani, and P.E. Scherer. 2005. Adiponectin: a relevant player in PPARγ-agonist mediated improvements in hepatic insulin sensitivity? International Journal of Obesity and Related Metabolic Disorders 29(Suppl. 1): S17–S23.CrossRef
52.
Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8: 731–737.PubMedCrossRef
53.
Berg, A.H., T.P. Combs, X. Du, M. Brownlee, and P.E. Scherer. 2001. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Medicine 7: 947–953.PubMedCrossRef
54.
Cook, K.S., H.Y. Min, D. Johnson, R.J. Chaplinsky, J.S. Flier, C.R. Hunt, and B.M. Spiegelman. 1987. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science 237(4813): 402–405.PubMedCrossRef
55.
Uysal, K.T., S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389(6651): 610–614.PubMedCrossRef
56.
Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259(5091): 87–91.PubMedCrossRef
57.
Hotamisligil, G.S. 1999. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. Journal of Internal Medicine 245: 621–625.PubMedCrossRef
Metadata
Title
Adipocytokine Levels in Obese and Non-obese Subjects: an Observational Study
Authors
Giuseppe Derosa
Elena Fogari
Angela D’Angelo
Lucio Bianchi
Aldo Bonaventura
Davide Romano
Pamela Maffioli
Publication date
01-08-2013
Publisher
Springer US
Published in
Inflammation / Issue 4/2013
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9620-4

Other articles of this Issue 4/2013

Inflammation 4/2013 Go to the issue

OriginalPaper

C-Reactive Protein Measurements as a Marker of the Severity of Chronic Obstructive Pulmonary Disease Exacerbations

OriginalPaper

The Effect of Synthetic C-Reactive Protein on the In Vitro Immune Response of Human PBMCs Stimulated with Bacterial Reagents

OriginalPaper

Low-dose Interferon-α Treatment Improves Survival and Inflammatory Responses in a Mouse Model of Fulminant Acute Respiratory Distress Syndrome

OriginalPaper

B7-H4’s Role “Beyond the Tumor”

OriginalPaper

IL-17A/F Modulates Fibrocyte Functions in Cooperation with CD40-Mediated Signaling

OriginalPaper

Lypopolysaccharide Downregulates the Expression of Selected Phospholipase C Genes in Cultured Endothelial Cells
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits